Auteur N. SINGLETON

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Captagon: understanding today's illicit market

OEDT = EMCDDA ; L. LANIEL ; M. GANDILHON ; J. E. ADES ; A. CUNNINGHAM ; N. SINGLETON ; R. SEDEFOV ; P. GRIFFITHS | 2018
Rapport

Captagon is reported to be a commonly used stimulant in the Middle East. In addition, some recent media reports have linked this drug to perpetrators of terrorist acts in Europe or terrorist groups based in areas of conflict in the Middle East. [...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Nouveauté

Drug affordability - potential tool for comparing illicit drug markets

T. GROSHKOVA ; A. CUNNINGHAM ; L. ROYUELA ; N. SINGLETON ; T. SAGGERS ; R. SEDEFOV | 2018
Dans International Journal of Drug Policy (Vol.56, June 2018) Article : Périodique

Background: The importance of illicit drug price data and making appropriate adjustments for purity has been repeatedly highlighted for understanding illicit drug markets. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has [...]

Plus d'info

Ajouter à la sélection

Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus expert network

OEDT = EMCDDA ; I. GIRAUDON ; A. M. DINES ; N. SINGLETON ; A. NOOR ; P. I. DARGAN ; D. WOOD | 2020
Rapport

ENGLISH: This report presents the latest findings on drug-related hospital emergencies from a network of sentinel hospitals across Europe. Almost 24 000 emergency presentations were recorded at 32 sentinel hospitals over the first 4 years of th[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Nouveauté

Drug supply indicators: Pitfalls and possibilities for improvements to assist comparative analysis

N. SINGLETON ; A. CUNNINGHAM ; T. GROSHKOVA ; L. ROYUELA ; R. SEDEFOV | 2018
Dans International Journal of Drug Policy (Vol.56, June 2018) Article : Périodique

Interventions to tackle the supply of drugs are seen as standard components of illicit drug policies. Therefore drug market-related administrative data, such as seizures, price, purity and drug-related offending, are used in most countries for p[...]

Plus d'info

Ajouter à la sélection

Drug use and initiation in prison: results from a national prison survey in England and Wales

A. BOYS ; M. FARRELL ; P. BEBBINGTON ; BRUGHA T. ; COID J. ; R. JENKINS ; G. LEWIS ; J. MARSDEN ; MELTZER H. ; N. SINGLETON ; C. TAYLOR | 2002
Périodique

FRANÇAIS : En Angleterre et au Pays de Galle, 3142 prisonniers ont été soumis à une enquête par questionnaire concernant leurs caractéristiques démographiques, leur trajectoire sociale, leurs problèmes psychiatriques et leurs consommations de d[...]

Plus d'info

Ajouter à la sélection

Increasing access to hepatitis C testing and care for people who inject drugs

OEDT = EMCDDA ; D. HEDRICH ; K. PALCZAK ; K. KEPA ; N. SINGLETON | 2021
Rapport

This manual provides a step-by-step guide for those involved in planning and managing infectious diseases and drug services, focusing on how to identify barriers to and opportunities for improving provision of HCV testing and access to treatment[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Measuring different aspects of problem drug use: methodological developments

N. SINGLETON, Éditeur scientifique ; R. MURRAY, Éditeur scientifique ; L. TINSLEY, Éditeur scientifique | 2006
Rapport

Home Office Online Report 16/06 brings together the results of three studies which provide robust updated estimates of the size of the illegal drug use problem, from different perspectives. The new studies build on earlier studies but all contai[...]

Plus d'info

Ajouter à la sélection

Lien externe

New psychoactive substances in prison. Results from an EMCDDA trendspotter study

OEDT = EMCDDA ; L. VANDAM ; P. BORLE ; L. MONTANARI ; T. SURMONT ; A. PIRONA ; D. HEDRICH ; A. GALLEGOS ; N. SINGLETON ; J. MOUNTENEY ; P. GRIFFITHS | 2018
Rapport

This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large sha[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Surveying drug consumption: Assessing reliability and validity of the European Web Survey on Drugs questionnaire

K. SKARUPOVA ; N. SINGLETON ; J. MATIAS ; V. MRAVCIK | 2019
Dans International Journal of Drug Policy (Vol.73, November 2019) Article : Périodique

Background: The European Web Survey on Drugs aimed to obtain in-depth data on consumption of cannabis, ecstasy/MDMA, cocaine, and amphetamines in different populations of drug users in 16 European countries. This paper examines test-retest relia[...]

Plus d'info

Ajouter à la sélection

Taking drugs seriously: A Demos and UK Drug Policy Commission report on legal highs

J. BIRDWELL ; J. CHAPMAN ; N. SINGLETON | 2011
Rapport

The proliferation of new psychoactive substances, or 'legal highs', in recent years has thrown the existing regulatory measures for drugs into sharp relief. As quickly as policy makers seek to control new substances through the Misuse of Drugs A[...]

Plus d'info

Ajouter à la sélection

Lien externe

The use of multi-national web surveys for comparative analysis: Lessons from the European Web Survey on Drugs

J. MATIAS ; E. KALAMARA ; F. MATHIS ; K. SKARUPOVA ; A. NOOR ; N. SINGLETON | 2019
Dans International Journal of Drug Policy (Vol.73, November 2019) Article : Périodique

Background: Most comparative drug policy analyses utilise measures of drug use, often from general population surveys (GPS). However, the limitations of GPS are well-recognised, including the small numbers of people who use illicit drugs sampled[...]

Plus d'info

Ajouter à la sélection

Using open-source information to improve the European drug monitoring system

OEDT = EMCDDA ; T. GROSHKOVA ; A. CUNNINGHAM ; N. SINGLETON ; T. STOIAN ; R. SEDEFOV | 2019
Rapport

This paper describes open-source information monitoring and how we use it at the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in the area of drug markets - what it is and, importantly, what it is not; the methodology for its [...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Using supply indicators in the evaluation of drug supply reduction - Challenges and opportunities

N. SINGLETON ; A. CUNNINGHAM ; T. GROSHKOVA ; L. ROYUELA ; R. SEDEFOV ; P. GRIFFITHS | 2023
Chapitre

Interventions to tackle the supply of drugs, are seen as standard components of illicit drug policies and drug market-related administrative data, such as seizures, price, purity and drug-related offending, are widely used for policy monitoring [...]

Plus d'info

Ajouter à la sélection

What would an evidence based drug policy be like? [Editorial]

N. SINGLETON ; J. STRANG | 2014
Dans British Medical Journal (Vol.349, n°7987, 13 December 2014) Article : Périodique

Policy must move beyond evidence based to evidence infused to produce public good. In their foreword to the UK Home Office's comparison of drug policies in various countries, government ministers stated that "the UK will continue to advocate a [...]

Plus d'info

Ajouter à la sélection

Will the current COVID-19 pandemic impact on long-term cannabis buying practices? [Commentary]

T. GROSHKOVA ; T. STOIAN ; A. CUNNINGHAM ; P. GRIFFITHS ; N. SINGLETON ; R. SEDEFOV | 2020
Dans Journal of Addiction Medicine (Vol.14, n°4, July-August 2020) Article : Périodique

The COVID-19 pandemic and the response to have resulted in an increase in sales activity levels on darknet markets during the first 3 months of 2020, mainly related to cannabis products. One key question is whether more people will become used t[...]

Plus d'info

Ajouter à la sélection